Add Yahoo as a preferred source to see more of our stories on Google. Health and Human Services Secretary Robert F. Kennedy Jr. canceled $500 million of funding for research on mRNA vaccine technology ...

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...

Add Yahoo as a preferred source to see more of our stories on Google. RFK Jr. canceled $500 million of funding for research on mRNA vaccine technology. Anadolu/Getty Images At a Sept. 4, 2025, hearing ...

In August last year, the Health Department cut around $500 million in mRNA research funding, with Health Secretary Robert F.

Announced days before a trial, the deal settles a longstanding dispute and avoids what one analyst called a “worst-case ...

WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...

IBM and Moderna have achieved a groundbreaking milestone by simulating the longest mRNA pattern without the use of AI, instead leveraging the power of quantum computing. This collaboration marks a ...

Commissioner Marty Makary defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...

In recent years, mRNA in lipid nanoparticles (mRNA–LNPs) has emerged as a promising strategy for treating numerous conditions ...

The success of mRNA technology and its potential uses in therapeutics and preventative medical treatment may create a new technology ecosystem, the Harvard Business Review reported April 18. As has ...

Messenger RNA (mRNA) technology is transforming medicine by providing our cells with genetic instructions to produce proteins that help the immune system prevent or fight a wide range of diseases, ...

Researchers developed an mRNA delivery system designed to improve embryo implantation. This approach could enhance ART outcomes and address uterine-factor infertility, with pre-clinical studies ...